What is the standard of care for locally advanced Kidney Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Kidney Cancer (NCCN Guidelines)

What "Locally Advanced" Means

Locally advanced kidney cancer refers to Stage II and Stage III disease—tumors that have grown beyond the kidney itself but haven't spread to distant organs like the lungs or bones. According to the NCCN Guidelines Version 1.2026 for Kidney Cancer, this includes:

• Stage II: Larger tumors (>7 cm) confined to the kidney
• Stage III: Tumors that extend into nearby structures like the renal vein, inferior vena cava (the large vein returning blood to the heart), or regional lymph nodes

---

Primary Treatment: Radical Nephrectomy

The standard of care for locally advanced kidney cancer is radical nephrectomy—surgical removal of the entire affected kidney, surrounding fat, and the adrenal gland (if involved).

According to NCCN Guidelines, radical nephrectomy is the curative therapy for patients with Stage II and III disease. This is particularly important for tumors extending into the inferior vena cava, which may require specialized surgical teams and sometimes assistance from cardiovascular surgeons due to the complexity of the procedure.

Key Surgical Considerations:

Lymph Node Dissection:

• Regional lymph node dissection should be considered for patients with:

  • Enlarged lymph nodes visible on imaging before surgery
  • Lymph nodes that can be felt or seen during surgery

• The NCCN notes that while lymph node dissection doesn't consistently improve overall survival, it may help with accurate staging and identifying patients who might benefit from additional treatment.

Adrenal Gland Removal:

• Adrenalectomy (removal of the adrenal gland) should be considered for large upper-pole tumors or abnormal-appearing adrenal glands on imaging
• If the adrenal gland appears normal, it may be preserved to maintain hormone function

---

After Surgery: Adjuvant Therapy Considerations

For patients with clear cell histology (the most common type, ~70% of cases) who have had complete surgical removal of their tumor, the NCCN Guidelines recommend:

• Adjuvant Pembrolizumab (an immunotherapy drug) OR
• Surveillance (close monitoring with imaging and blood work)

For patients with non-clear cell histology (papillary, chromophobe, and other types):

• Surveillance OR
• Clinical trial enrollment (preferred option)

---

Special Situations

Patients Not Optimal Surgical Candidates:

If a patient cannot tolerate surgery due to poor health status or other medical conditions, alternative options include:

• Stereotactic Body Radiation Therapy (SBRT) - focused radiation treatment (Category 2A recommendation for Stage II, Category 3 for Stage III)
• Percutaneous ablation - minimally invasive techniques like cryotherapy or radiofrequency ablation (though less commonly used for advanced stages)
• Active surveillance - careful monitoring if the patient has significant competing health risks

---

Follow-Up After Treatment

According to NCCN Guidelines, follow-up should be individualized based on:

• Tumor stage and grade
• Pathologic features
• Patient's overall health
• Imaging findings

Follow-up typically includes periodic imaging (CT or MRI) and blood work to monitor for recurrence.

---

Key Questions to Ask Your Oncology Team

1. Is my tumor technically resectable? (Can it be completely removed surgically?)
2. What is my performance status, and am I a good surgical candidate?
3. Will I need lymph node dissection, and why or why not?
4. After surgery, will I be a candidate for adjuvant pembrolizumab, or is surveillance appropriate for me?
5. What is the follow-up plan, and how often will I need imaging and blood work?
6. Are there clinical trials available for my specific situation?

---

Important Context

The NCCN emphasizes that treatment decisions should be individualized based on your complete clinical picture, including tumor characteristics, your overall health, kidney function, and your preferences. High-volume cancer centers with experience in complex kidney cancer surgery may be particularly valuable for locally advanced cases, especially those involving the vena cava.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.